Early-phase clinical trial data, including results from a Phase 2 randomised controlled trial published in The New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023), demonstrated significant weight reduction in adults with obesity (without type 2 diabetes), with participants receiving the highest dose losing a mean of approximately 24% of their body weight over 48 weeks
GLP-1 and exendin-4 show a similar nM affinity while glucagon, secretin, VIP and GLP-2 have at least a hundred times lower affinity for the GLP-1 receptor
Shima Hadidchi, MD Family Practice, we are committed to staying at the forefront of medical advancements
Smoothie King launched a GLP-1 Support Menu featuring smoothies with 20 grams of protein or more and no added sugar
Emerging brands like Replenza, Keptropy, and FullWell are marketing GLP-1-supportive supplements via direct-to-consumer channels, with emphasis on glycemic control, lean mass preservation, and post-meal tolerance
DESCRIPTION TABLE OF CONTENTS METHODOLOGY DOWNLOAD PDF GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033 USD 170.75 BN MARKET SIZE, 2033 OVERVIEW Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis The global GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period
